{"id":"NCT05109702","sponsor":"HanAll BioPharma Co., Ltd.","briefTitle":"A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye","officialTitle":"A Phase 3, Multicenter, Randomized, Double Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% Compared to Placebo in Subjects With Dry Eye","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-11-18","primaryCompletion":"2022-05-06","completion":"2022-05-06","firstPosted":"2021-11-05","resultsPosted":"2023-10-23","lastUpdate":"2023-10-23"},"enrollment":260,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye"],"interventions":[{"type":"DRUG","name":"0.25% Tanfanercept Ophthalmic Solution","otherNames":["HL036"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo Run-in","type":"OTHER"},{"label":"0.25% Tanfanercept Ophthalmic Solution","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.","primaryOutcome":{"measure":"Change From Baseline in Central Corneal Staining Score (CCSS) at Day 57","timeFrame":"Baseline, Day 57 (Week 8)","effectByArm":[{"arm":"0.25% Tanfanercept Ophthalmic Solution","deltaMin":2.4,"sd":0.497},{"arm":"Placebo","deltaMin":2.37,"sd":0.477}],"pValues":[{"comp":"OG000 vs OG001","p":"0.764"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["36729473"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":260},"commonTop":["Instillation site pain","Visual acuity reduced","COVID-19","Conjunctivitis allergic","Urinary tract infection"]}}